Metrics to compare | NYMXF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNYMXFPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −1.3x | −0.2x | |
PEG Ratio | −0.12 | 0.00 | 0.00 | |
Price/Book | - | 0.6x | 2.6x | |
Price / LTM Sales | - | 3.0x | 2.8x | |
Upside (Analyst Target) | - | 270.4% | 65.0% | |
Fair Value Upside | Unlock | 1.8% | 9.5% | Unlock |
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma. The company also offers NicAlert, a simple, cost-effective test for determining smoking status; and TobacAlert, a test for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment and prevention of Alzheimer’s disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, Bahamas.